11,383 results match your criteria Bone Marrow Transplantation[Journal]


Safety and feasibility of outpatient autologous stem cell transplantation in pediatric patients with primary central nervous system tumors.

Bone Marrow Transplant 2019 Feb 19. Epub 2019 Feb 19.

Department of Pediatric Hematology/Oncology/Bone Marrow Transplant, University of Colorado, Children's Hospital Colorado, Aurora, CO, USA.

High-dose chemotherapy with autologous hematopoietic stem cell transplantation (autoHSCT) is a well-established treatment for pediatric central nervous system (CNS) tumors. Given the risks of toxicity and infection, pediatric autoHSCT has been historically performed on hospitalized children. As our practice evolved, some patients were transplanted as outpatients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0479-3DOI Listing
February 2019

Efficacy and safety of autologous stem cell transplantation in patients aged ≥ 65 years with multiple myeloma in the era of novel agents.

Bone Marrow Transplant 2019 Feb 19. Epub 2019 Feb 19.

Division of Hematology, Department of Internal Medicine, Aichi Medical University, Nagakute, Japan.

Clinical trials evaluating the role of autologous hematopoietic stem cell transplantation (auto-HCT) in multiple myeloma have mostly included patients aged <65 years. Therefore, this study was aimed to evaluate the efficacy and safety of auto-HCT in elderly patients with multiple myeloma in the era of novel agents. We retrospectively analyzed 2056 patients with multiple myeloma, who underwent auto-HCT in 2007-2014 (287 were aged ≥65 years). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0478-4DOI Listing
February 2019

"Worldwide Network for Blood & Marrow Transplantation (WBMT) special article, challenges facing emerging alternate donor registries".

Bone Marrow Transplant 2019 Feb 18. Epub 2019 Feb 18.

Adult Hematology/HSCT, Oncology Centre, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.

Hematopoietic cell transplantation (HCT) activity is increasing at an unprecedented pace with > 50,000 allogeneic transplants occurring annually worldwide. Establishing a functional HCT donor registry can be very challenging with respect to ethnicities, financial, technical, and geopolitical issues. Extensive planning steps are essential to overcome the expected challenges while establishing the registry, and to maintain its functionality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0476-6DOI Listing
February 2019

Patients vary: so do wines.

Authors:
Shaun McCann

Bone Marrow Transplant 2019 Feb 15. Epub 2019 Feb 15.

University of Dublin Trinity College, Haematology Emeritus, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0477-5DOI Listing
February 2019

Evaluation of infectious complications after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide following reduced-intensity and myeloablative conditioning: a study on behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC).

Bone Marrow Transplant 2019 Feb 15. Epub 2019 Feb 15.

Institut de Cancérologie Lucien Neuwirth, Saint-Etienne, France.

Several approaches have been developed to overcome historical barriers associated with poor outcomes in the setting of HLA-haploidentical allogeneic transplantation (HaploSCT). Here, we examine the outcome of patients with various hematological disorders undergoing HaploSCT with high-dose, post-transplantation cyclophosphamide. We performed a retrospective study on 381 patients from 30 centers between January 2013 and December 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0475-7DOI Listing
February 2019

Author Correction: Donor lymphocyte infusions for B-cell malignancies relapse after T-cell replete allogeneic hematopoietic cell transplantation.

Bone Marrow Transplant 2019 Feb 7. Epub 2019 Feb 7.

Hematology Department, Hospital Universitari Vall d´Hebron, Departament de Medicina, Universitat Autonoma de Barcelona, Barcelona, Spain.

In the original version of this article, author 'Lucia López-Corral' was incorrectly listed as 'Lucia López'. This has now been corrected in both the PDF and HTML versions of the article to 'Lucia López-Corral'. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0471-yDOI Listing
February 2019

The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies.

Bone Marrow Transplant 2019 Feb 6. Epub 2019 Feb 6.

Department of Stem Cell Transplantation, University Hospital Eppendorf, Hamburg, Germany.

Hematopoietic cell transplantation (HCT) is widely used for acquired and congenital disorders of the hematopoietic system. Number of transplants done in Europe and associated countries continues to rise with 45,418 HCT in 41,100 patients [(17,155 allogeneic (42%) and 23,945 autologous (58%)] reported by 683 centers in 50 countries in 2017. Main indications were myeloid malignancies 10,147 (25%; 96% allogeneic), lymphoid malignancies 26,488 (64%; 19% allogeneic), solid tumors 1,607 (3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0465-9DOI Listing
February 2019
1 Read

T-cell frequencies of CD8 γδ and CD27 γδ cells in the stem cell graft predict the outcome after allogeneic hematopoietic cell transplantation.

Bone Marrow Transplant 2019 Feb 5. Epub 2019 Feb 5.

Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.

The impact of intra-graft T cells on the clinical outcome after allogeneic hematopoietic cell transplantation has been investigated. Most previous studies have focused on the role of αβ cells while γδ cells have received less attention. It has been an open question whether γδ cells are beneficial or not for patient outcome, especially with regards to graft versus host disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0462-zDOI Listing
February 2019
1 Read

Clinical impact of the loss of chromosome 7q on outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem cell transplantation.

Bone Marrow Transplant 2019 Feb 4. Epub 2019 Feb 4.

Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan.

We conducted a nationwide retrospective study to evaluate the prognostic influence of +1, der(1;7)(q10;p10) [hereafter der(1;7)] and -7/del(7q) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for de novo myelodysplastic syndromes (MDS). In this database, 69 MDS patients with der(1;7), 75 with -7/del(7q), and 511 with normal karyotype (NK) underwent allo-HSCT at advanced disease status. The 3-year overall survival (OS) and cumulative incidence of relapse (CIR) were 50. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0469-5DOI Listing
February 2019
2 Reads

Cryotherapy as prophylaxis against oral mucositis after high-dose melphalan and autologous stem cell transplantation for myeloma: a randomised, open-label, phase 3, non-inferiority trial.

Bone Marrow Transplant 2019 Feb 4. Epub 2019 Feb 4.

Department of Oral Medicine and Pathology, Institute of Odontology, The Sahlgrenska Academy at Göteborg University, Göteborg, Sweden.

The conditioning therapy used in connection with haematopoietic stem cell transplantation (HSCT) can induce painful oral mucositis, which has negative impacts on patient quality of life and survival, as well as on health-care costs. While cooling of the oral mucosa (cryotherapy) is regarded as standard prophylaxis against oral mucositis, the long duration of the treatment affects compliance owing to side effects. In this prospective, randomised trial, 94 patients (62 males/32 females; median age 59 years, range 34-69) with a diagnosis of myeloma who were undergoing autologous HSCT were randomised 1:1 to receive cryotherapy for 7 h (N = 46) or 2 h (N = 48). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0468-6DOI Listing
February 2019
1 Read

Less mucositis toxicity after 6 versus 3 fractions of high-dose total body irradiation before allogeneic stem cell transplantation.

Bone Marrow Transplant 2019 Feb 4. Epub 2019 Feb 4.

Department of Oncology, Rigshospitalet, Copenhagen, Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0470-zDOI Listing
February 2019

Hematopoietic stem-cell transplantation in children with refractory acute myeloid leukemia.

Bone Marrow Transplant 2019 Feb 4. Epub 2019 Feb 4.

Department of Pediatrics, Kyoto City Hospital, 1-2 Mibuhigashitakadacho, Nakagyo Ward, Kyoto, 604-8845, Japan.

Allogeneic hematopoietic stem cell transplantation (HSCT) can be used to treat children with refractory acute myeloid leukemia (AML). This retrospective analysis aimed to describe the outcomes and risk factors in such children. Data were collected through the nation-wide registry program in Japan. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41409-019-0461-0
Publisher Site
http://dx.doi.org/10.1038/s41409-019-0461-0DOI Listing
February 2019
5 Reads

Severe renal insufficiency is not an absolute pitfall to autologous stem cell transplantation with BeEAM (bendamustine, etoposide, cytarabine, melphalan) conditioning regimen.

Bone Marrow Transplant 2019 Feb 4. Epub 2019 Feb 4.

Hematology and Cellular Therapy Department, La Conception, University Hospital of Marseille, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0467-7DOI Listing
February 2019

Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT.

Bone Marrow Transplant 2019 Feb 4. Epub 2019 Feb 4.

Acute Leukemia Working Party of EBMT, Paris, France.

Refractory or relapsed acute myeloid leukemia (R/R-AML) has poor prognosis. Allogeneic hematopoietic stem-cell transplantation (HSCT) may provide cure in this scenario. We compared outcomes of HSCT from HLA-identical (HLA-id, n = 1654) sibling or haploidentical (Haplo, n = 389) donors in patients with R/R-AML, performed during the period 2007-2015. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41409-019-0459-7
Publisher Site
http://dx.doi.org/10.1038/s41409-019-0459-7DOI Listing
February 2019
3 Reads

BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomas.

Bone Marrow Transplant 2019 Feb 4. Epub 2019 Feb 4.

Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.

High-dose chemotherapy followed by autologous hematopoietic cell transplantation (AHCT) is an effective salvage therapy for patients with relapsed chemosensitive non-Hodgkin's lymphoma (NHL). However, the optimal conditioning regimen is unclear. Different conditioning regimens prior to AHCT have been used with the two most common being BEAM (carmustine, etoposide, cytarabine, and melphalan) and BUCYVP16 (busulfan, cyclophosphamide, and etoposide). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0463-yDOI Listing
February 2019
1 Read

Blood and Wine.

Authors:
Shaun McCann

Bone Marrow Transplant 2019 Feb 4. Epub 2019 Feb 4.

Department of Haematology and Academic Medicine, St James' Hospital and Trinity College, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0466-8DOI Listing
February 2019

FLT3 internal tandem duplication does not impact prognosis after haploidentical allogeneic hematopoietic stem cell transplantation in AML patients.

Bone Marrow Transplant 2019 Feb 1. Epub 2019 Feb 1.

Peking University People's Hospital, Peking University Institute of Hematology, Beijing, P.R. China.

Acute myelogenous leukemia (AML) patients with fetal liver tyrosine kinase 3 (FLT3) internal tandem duplications (ITDs) have poor prognoses if treated with chemotherapy only, primarily as they experience increased relapse rates. To determine whether this alteration also affects outcomes after haploidentical donor (HID) allogeneic hematopoietic stem cell transplantation (allo-HSCT), we compared 334 consecutive FLT3-ITD-positive vs -negative patients with AML (other than acute promyelocytic leukemia) who underwent HID-HSCT. FLT3-ITD was detected in 39 of 334 patients (11. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0456-xDOI Listing
February 2019
2 Reads

General information for patients and carers considering haematopoietic stem cell transplantation (HSCT) for severe autoimmune diseases (ADs): A position statement from the EBMT Autoimmune Diseases Working Party (ADWP), the EBMT Nurses Group, the EBMT Patient, Family and Donor Committee and the Joint Accreditation Committee of ISCT and EBMT (JACIE).

Bone Marrow Transplant 2019 Jan 31. Epub 2019 Jan 31.

Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield S10 2JF, UK.

Over the last 20 years, haematopoietic stem cell transplantation (HSCT) has been used to treat patients with severe autoimmune and inflammatory diseases whose response to standard treatment options has been limited, resulting in a poor long-term prognosis in terms of survival or disability. The vast majority of patients have received autologous HSCT where an increasing evidence-base supports its use in a wide range of autoimmune diseases, particularly relapsing remitting MS, systemic sclerosis and Crohn's disease. Compared with standard treatments for autoimmune diseases, HSCT is associated with greater short-term risks, including a risk of treatment-related mortality and long-term complications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0430-7DOI Listing
January 2019

A novel strategy for identifying early acute kidney injury in pediatric hematopoietic stem cell transplantation.

Bone Marrow Transplant 2019 Jan 30. Epub 2019 Jan 30.

University of Cincinnati College of Medicine, Cincinnati, OH, USA.

Acute kidney injury (AKI) is a common complication in pediatric hematopoietic stem cell transplantation (HSCT). Serum creatinine is an imprecise biomarker of AKI. We hypothesized that combining creatinine with serum cystatin C (cysC) and urinary neutrophil gelatinase-associated lipocalin (NGAL) more effectively characterizes AKI during the first 28 days of HSCT and better identifies patients at risk of adverse outcomes than creatinine alone. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-018-0428-6DOI Listing
January 2019
1 Read

Providing both autologous and allogeneic hematopoietic stem cell transplants (HSCT) may have a stronger impact on the outcome of autologous HSCT in adult patients than activity levels or implementation of JACIE at Belgian transplant centres.

Bone Marrow Transplant 2019 Jan 29. Epub 2019 Jan 29.

CHU de Liège, Liège, Belgium.

While performance since the introduction of the JACIE quality management system has been shown to be improved for allogeneic hematopoietic stem cell transplants (HSCT), impact on autologous-HSCT remains unclear in Europe. Our study on 2697 autologous-HSCT performed in adults in 17 Belgian centres (2007-2013) aims at comparing the adjusted 1 and 3-yr survival between the different centres & investigating the impact of 3 centre-related factors on performance (time between JACIE accreditation achievement by the centre and the considered transplant, centre activity volume and type of HSCT performed by centres: exclusively autologous vs both autologous & allogeneic). We showed a relatively homogeneous performance between Belgian centres before national completeness of JACIE implementation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0458-8DOI Listing
January 2019
1 Read

Psychosocial Assessment of Candidates for Transplant (PACT) as a tool for psychological and social evaluation of allogeneic hematopoietic cell transplantation recipients.

Bone Marrow Transplant 2019 Jan 29. Epub 2019 Jan 29.

Blood & Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

Psychosocial Assessment of Candidates for Transplant (PACT) is a tool originally developed to address psychosocial risks in solid organ transplant recipients and has the potential for application to hematopoietic cell transplantation (HCT) recipients. In a retrospective cohort study, we reviewed 404 adult allogeneic HCT cases from 2003 to 2014 to identify predictors of adverse psychosocial status as determined by PACT. Final PACT rating was poor/borderline (score 0-1) in 5%, acceptable (score 2) in 22%, good (score 3) in 44%, and excellent (score 4) in 29% recipients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0455-yDOI Listing
January 2019

Virus detection in the cerebrospinal fluid of hematopoietic stem cell transplant recipients is associated with poor patient outcomes: a CIBMTR contemporary longitudinal study.

Bone Marrow Transplant 2019 Jan 29. Epub 2019 Jan 29.

Division of Hematology/Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Limited data exist on characteristics of central nervous system viruses (CNS-V) in allogeneic hematopoietic stem cell transplant (HCT) recipients. Between 2007 and 2015, the Center for International Blood and Marrow Transplant Research (CIBMTR) received information on 27,532 patients undergoing HCT. Of these, centers reported 165 HCT recipients with CNS-V detected in cerebrospinal fluid within 6 months after HCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0457-9DOI Listing
January 2019
2 Reads

Assessment of the proposed EBMT pediatric criteria for diagnosis and severity grading of sinusoidal obstruction syndrome.

Bone Marrow Transplant 2019 Jan 25. Epub 2019 Jan 25.

Institute for Inflammation Research, Department of Rheumatology and Spine Disease, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.

Sinusoidal obstruction syndrome (SOS) is a potentially life-threatening complication of allogeneic hematopoietic stem cell transplantation (HSCT). We assessed the proposed pediatric EBMT criteria along with the Baltimore and modified Seattle criteria in a population-based cohort. Eighty-seven children (1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-018-0426-8DOI Listing
January 2019
2 Reads

G-CSF-induced macrophage polarization and mobilization may prevent acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Bone Marrow Transplant 2019 Jan 25. Epub 2019 Jan 25.

Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Collaborative Innovation Center of Hematology, Beijing, China.

Macrophages (MΦs) are an important immune cell population that are essential for tissue homeostasis and disease pathogenesis. MΦs are now classified as either M1, which produce pro-inflammatory cytokines, or M2, which produce antiinflammatory cytokines. The impact of granulocyte colony-stimulating factor (G-CSF) on MΦs in humans is unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0449-9DOI Listing
January 2019
1 Read

Ultrasound elastography techniques for diagnosis and follow-up of hepatic veno-occlusive disease.

Bone Marrow Transplant 2019 Jan 24. Epub 2019 Jan 24.

Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0432-5DOI Listing
January 2019
1 Read

The new refined minnesota risk score for acute graft-versus-host disease predicts overall survival and non-relapse mortality after T cell-replete haploidentical stem cell transplant with post-transplant cyclophosphamide.

Bone Marrow Transplant 2019 Jan 24. Epub 2019 Jan 24.

Bone Marrow Transplant Unit, Humanitas Clinical and Research Center, Rozzano, Italy.

We propose to test whether the new refined Minnesota risk score, which represents a new tool for acute Graft-versus-Host-Disease (aGVHD) grading, may be useful to predict the final outcome of patients with aGVHD after haploidentical stem cell transplantation (Haplo-SCT) with post-transplant cyclophosphamide (PT-Cy). Hundred consecutive patients with grade 2-4 aGVHD were included. Twenty-two percent of the patients had high-risk (HR) aGVHD and had a lower chance to respond at day 28: 41% of non-responders (NR) were in the HR vs 13% in the standard-risk (SR) group (p = 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0453-0DOI Listing
January 2019
3 Reads

Outcome of allografting for AML-CR2 is equivalent across BSBMT and EBMT and is associated with encouraging OS and DFS across all age groups.

Bone Marrow Transplant 2019 Jan 24. Epub 2019 Jan 24.

British Society for Blood and Marrow Transplantation, Guys and St Thomas Hospital, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0439-yDOI Listing
January 2019

Eltrombopag for post-transplant cytopenias due to poor graft function.

Bone Marrow Transplant 2019 Jan 24. Epub 2019 Jan 24.

Hematology, Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy.

Persistent cytopenia due to poor graft function (PoGF) is a relatively common complication which may affect up to 20% of patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Treatment options for PoGF remain limited, and reinfusion of additional HSC is often the only way to rescue hematopoiesis. Here we describe a retrospective single-center experience with the thrombopoietin-mimetic agent eltrombopag for the treatment of PoGF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0442-3DOI Listing
January 2019

Immunosuppressive therapy versus haploidentical transplantation in adults with acquired severe aplastic anemia.

Bone Marrow Transplant 2019 Jan 22. Epub 2019 Jan 22.

Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.

Our study aimed to compare treatment outcomes between hematopoietic stem cell transplantation (HSCT) from haploidentical donors (HID) and immunosuppressive therapy (IST) in adults with acquired severe aplastic anemia (SAA). The medical records of 113 SAA adults who received IST, including rabbit ATG and cyclosporin (N = 37), or HID HSCT (N = 76) within 6 months of diagnosis at two institutions were retrospectively reviewed. Estimated 8-year overall survival (OS) was comparable between the IST and HID HSCT groups (75. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-018-0410-3DOI Listing
January 2019
1 Read

Clinical significance of low-dose total body irradiation in HLA-mismatched reduced-intensity stem cell transplantation.

Bone Marrow Transplant 2019 Jan 22. Epub 2019 Jan 22.

Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan.

The significance of low-dose total body irradiation (TBI) in HLA-mismatched reduced-intensity conditioning stem cell transplantation (RICT) remains unknown. We, retrospectively, evaluated the impact of low-dose TBI in patients with hematological malignancies who received first RICT from ≥1 antigen-mismatched donors between 2004 and 2014. Of the 575 patients, 361 patients received low-dose TBI (2 or 4 Gy). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0434-3DOI Listing
January 2019

Nationwide survey in France on the use of romiplostim in patients with refractory severe aplastic anemia.

Bone Marrow Transplant 2019 Jan 22. Epub 2019 Jan 22.

Centre de Référence Aplasie Médullaire, Service d'Hématologie Greffe, Assistance Publique des Hôpitaux de Paris, Hôpital Saint-Louis, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0452-1DOI Listing
January 2019
1 Read

Prognosis of relapse after hematopoietic cell transplant (HCT) for treatment of leukemia or myelodysplastic syndrome (MDS) in children.

Bone Marrow Transplant 2019 Jan 22. Epub 2019 Jan 22.

Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA.

We studied 232 consecutive children transplanted between 1990 and 2011 with relapse after first hematopoietic cell transplant (HCT). Kaplan-Meier survival and hazard ratios for mortality were calculated for factors known at time of relapse using Cox proportional hazards models. The median (range) age at time of first HCT was 10. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0438-zDOI Listing
January 2019
1 Read

Improving security of autologous hematopoietic stem cell transplant in patients with light-chain amyloidosis.

Bone Marrow Transplant 2019 Jan 21. Epub 2019 Jan 21.

Amyloidosis and Multiple Myeloma Unit, Department of Hematology, Hospital Clínic of Barcelona, Barcelona, Spain.

Autologous stem cell transplant (ASCT) has demonstrated to be an effective treatment for patients with light-chain (AL) amyloidosis. However, a high transplant-related mortality (TRM) rate was reported in previous series of patients and questioned the role of transplant in this disease. Recently, experienced groups have shown a significant TRM decrease that has been attributed to an accurate selection of patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0447-yDOI Listing
January 2019
2 Reads

High-dose melphalan and autologous peripheral blood stem cell transplantation in patients with AL amyloidosis and cardiac defibrillators.

Bone Marrow Transplant 2019 Jan 21. Epub 2019 Jan 21.

Amyloidosis Center, Boston University School of Medicine, Boston, MA, USA.

Cardiac deposition of misfolded light chains is the leading cause of morbidity and mortality in patients with immunoglobulin (AL) amyloidosis. Cardiac defibrillators can be used in the management of patients with advanced cardiac amyloidosis, but data concerning the use of these devices in patients undergoing treatment with high-dose melphalan followed by autologous peripheral blood stem cell transplantation (HDM/SCT) is limited. Herein we describe a single-institution experience of HDM/SCT in 15 patients with cardiac defibrillators. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0440-5DOI Listing
January 2019
2 Reads

VCAP-AMP-VECP as a preferable induction chemotherapy in transplant-eligible patients with aggressive adult T-cell leukemia-lymphoma: a propensity score analysis.

Bone Marrow Transplant 2019 Jan 21. Epub 2019 Jan 21.

Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.

A dose-intensified multi-agent chemotherapy regimen called VCAP-AMP-VECP was investigated in Japan as front-line therapy for patients with adult T-cell leukemia-lymphoma (ATL). Although a prospective randomized controlled study showed that VCAP-AMP-VECP was superior to CHOP, the trial was rather small and no subsequent studies confirmed the benefit of VCAP-AMP-VECP over CHOP. We conducted a retrospective analysis of transplant-eligible patients with ATL who received only VCAP-AMP-VECP or CHOP, incorporating inverse probability of treatment weighting (IPTW) using propensity scoring. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0446-zDOI Listing
January 2019
2 Reads

Eltrombopag is an effective and safe therapy for refractory thrombocytopenia after haploidentical hematopoietic stem cell transplantation.

Bone Marrow Transplant 2019 Jan 21. Epub 2019 Jan 21.

Peking University People's Hospital, Peking University Institute of Hematology, Beijing, P.R. China.

Refractory thrombocytopenia is a frequent and severe complication after haploidentical allogeneic hematopoietic stem cell transplantation (haplo-HSCT) and lacks effective treatment strategies. Eltrombopag has shown promising results in several thrombocytopenia disorders. We report 38 patients treated with eltrombopag for refractory thrombocytopenia after haplo-HSCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0435-2DOI Listing
January 2019
3 Reads

EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL).

Bone Marrow Transplant 2019 Jan 21. Epub 2019 Jan 21.

University of Heidelberg, Heidelberg, Germany.

Preliminary data suggest that allogeneic stem cell transplantation (allo-SCT) may be effective in T-prolymphocytic leukemia (T-PLL). The purpose of the present observational study was to assess the outcome of allo-SCT in patients aged 65 years or younger with a centrally confirmed diagnosis of T-PLL. Patients were consecutively registered with the EBMT at the time of transplantation and followed by routine EBMT monitoring but with an extended dataset. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41409-019-0448-x
Publisher Site
http://dx.doi.org/10.1038/s41409-019-0448-xDOI Listing
January 2019
5 Reads

Targeting the niche: depleting haemopoietic stem cells with targeted therapy.

Bone Marrow Transplant 2019 Jan 21. Epub 2019 Jan 21.

Dendritic Cell Research, ANZAC Research Institute, Sydney, NSW, Australia.

Haemopoietic stem cell transplantation is an expanding procedure worldwide but is associated with significant morbidity and mortality. Depletion of resident haemopoietic stem and progenitor cells (HSPC) is required for both autologous and allogeneic haemopoietic stem cell transplantation. Current conditioning protocols utilise chemotherapy or radiation to effectively reduce HSPC but are toxic in both the short and long term. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41409-019-0445-0
Publisher Site
http://dx.doi.org/10.1038/s41409-019-0445-0DOI Listing
January 2019
3 Reads

Cataracts and wine.

Authors:
Shaun R McCann

Bone Marrow Transplant 2019 Jan 18. Epub 2019 Jan 18.

University of Dublin Trinity College, Haematology Emeritus, Dublin, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0433-4DOI Listing
January 2019
1 Read

Transgender individuals represent an overlooked population amongst stem cell donors.

Bone Marrow Transplant 2019 Jan 18. Epub 2019 Jan 18.

Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0437-0DOI Listing
January 2019
1 Read

Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes.

Bone Marrow Transplant 2019 Jan 17. Epub 2019 Jan 17.

Department of Translational Hematology and Oncologic Research, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.

Next generation sequencing (NGS) has become an important tool to inform disease risk for myeloid malignancies, however data remains conflicting regarding the significance of individual mutations. We performed targeted NGS on 112 patients with AML, and 80 with MDS, who underwent allogeneic hematopoietic cell transplantation. The most common mutations in AML were TET2 (14. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41409-019-0444-1
Publisher Site
http://dx.doi.org/10.1038/s41409-019-0444-1DOI Listing
January 2019
4 Reads

Class I and II human leukocyte antibodies in pediatric haploidentical allograft candidates: prevalence and risk factors.

Bone Marrow Transplant 2019 Jan 17. Epub 2019 Jan 17.

Peking University People's Hospital and Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, No. 11 South Street of Xizhimen, Xicheng District, Beijing, 100044, P. R. China.

Donor-specific anti-human leukocyte antigen (HLA) antibodies (DSAs) were associated with graft failure (GF) following haploidentical stem cell transplantation (Haplo-HSCT). The prevalence and risk factors of DSAs in pediatric candidates remain to be determined. In a prospective trial (ChiCTR-OPC-15006672), 486 children with hematological diseases were enrolled to screen for the presence of anti-HLA class I and II antibodies of immunoglobulin G type. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-018-0427-7DOI Listing
January 2019
6 Reads

Tyrosine kinase inhibitor levels matter in treating chronic GVHD.

Bone Marrow Transplant 2019 Jan 16. Epub 2019 Jan 16.

Department of Hematology, University Medical Center Utrecht, Room number Q05.4.301, PO Box 85500, Utrecht, GA, 3508, The Netherlands.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41409-018-0429-5
Publisher Site
http://dx.doi.org/10.1038/s41409-018-0429-5DOI Listing
January 2019
3 Reads

Successful treatment of two relapsed/refractory t(8;21) acute myeloid leukemia patients by CD19-directed chimeric antigen receptor T cells.

Bone Marrow Transplant 2019 Jan 10. Epub 2019 Jan 10.

Department of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, 215000, Suzhou, China.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41409-018-0423-y
Publisher Site
http://dx.doi.org/10.1038/s41409-018-0423-yDOI Listing
January 2019
5 Reads
3.570 Impact Factor

Symptoms and signs.

Authors:
Shaun McCann

Bone Marrow Transplant 2019 Jan 10. Epub 2019 Jan 10.

University of Dublin Trinity College, Haematology, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-018-0425-9DOI Listing
January 2019
1 Read